Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$6.72
-3.9%
$4.91
$1.86
$9.01
$17.41M1.0368,125 shs129,449 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.29
$0.35
$0.10
$4.15
$19.16M-20.4711 shsN/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
$0.00
$0.00
$0.48
$8.14MN/A12.29 million shsN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
$1.95
$0.29
$5.25
$6.18M2.2957,354 shs164,300 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-3.86%+36.86%+35.76%+132.38%+72.62%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%-25.03%-32.00%+207.79%
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.5193 of 5 stars
3.53.00.00.02.30.80.0
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.00
Buy$16.00138.10% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest IMNP, BNTC, CHHE, and MTP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
2/15/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
1/24/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$80K217.56N/AN/A$0.12 per share56.00
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K174.22N/AN/A$0.60 per share0.49
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
$800K0.00N/AN/A$5.67 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$19.56MN/A0.00N/AN/A-204.34%-142.81%5/20/2024 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.02N/AN/A-89.33%-5.14%-4.24%N/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
-$7.51MN/A0.00N/AN/AN/AN/AN/AN/A

Latest IMNP, BNTC, CHHE, and MTP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q2 2024
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A-$0.01-$0.01-$0.01N/AN/A
2/13/2024Q2 2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A-$2.64-$2.64-$2.64N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/AN/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
0.01
3.62
3.62
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
0.04
0.04
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/AN/AN/A
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
52.19%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
1.43%
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
182.59 million2.48 millionNo Data
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
3265.54 million45.03 millionNot Optionable
Immune Pharmaceuticals Inc stock logo
IMNP
Immune Pharmaceuticals
N/A49.31 millionN/ANot Optionable
Biodexa Pharmaceuticals Plc stock logo
MTP
Biodexa Pharmaceuticals
1821.67 million21.60 millionNot Optionable

IMNP, BNTC, CHHE, and MTP Headlines

SourceHeadline
Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexas Investigational Drug Shows PotentialExtend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential
benzinga.com - March 28 at 1:49 PM
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
investorplace.com - March 28 at 12:11 PM
Biodex stock slides 7% amid data for two drug studiesBiodex stock slides 7% amid data for two drug studies
msn.com - February 23 at 8:57 PM
Why Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?Why Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?
msn.com - February 13 at 3:11 PM
Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares PlungeCrude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge
msn.com - December 19 at 4:01 PM
Biodexa Announces Pricing of $5.2 Million Underwritten Public OfferingBiodexa Announces Pricing of $5.2 Million Underwritten Public Offering
tmcnet.com - December 19 at 9:37 AM
Biodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting DeterminationBiodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting Determination
benzinga.com - July 8 at 9:54 AM
BDRX Biodexa Pharmaceuticals PlcBDRX Biodexa Pharmaceuticals Plc
seekingalpha.com - April 25 at 8:04 PM
Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of EquityBiodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity
finance.yahoo.com - April 4 at 3:25 PM
Why Is Midatech Pharma (BDRX) Stock Up 64% Today?Why Is Midatech Pharma (BDRX) Stock Up 64% Today?
investorplace.com - March 28 at 9:17 AM
Midatech Pharma PLC Announces Private Placement Raising US $6.0 millionMidatech Pharma PLC Announces Private Placement Raising US $6.0 million
finance.yahoo.com - February 9 at 3:29 PM
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcBioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
financialpost.com - January 23 at 9:28 AM
Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 StudyMidatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study
finance.yahoo.com - January 12 at 7:34 AM
BIOAF: Merger with Midatech PharmaBIOAF: Merger with Midatech Pharma
finance.yahoo.com - January 3 at 3:29 PM
Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies IncMidatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc
finance.yahoo.com - December 13 at 1:49 PM
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plcBioasis Technologies Inc. Announces Merger with Midatech Pharma plc
finance.yahoo.com - December 13 at 1:49 PM
MTP Midatech Pharma plcMTP Midatech Pharma plc
seekingalpha.com - October 11 at 12:50 PM
Midatech Pharma Will Need Extra Financing in 1Q 2023; Mulling OptionsMidatech Pharma Will Need Extra Financing in 1Q 2023; Mulling Options
marketwatch.com - September 14 at 10:02 PM
Midatech Pharma PLC Announces ADR Ratio ChangeMidatech Pharma PLC Announces ADR Ratio Change
finance.yahoo.com - September 14 at 10:17 AM
Midatech Pharma PLC NewsMidatech Pharma PLC News
thestreet.com - August 3 at 12:44 AM
Midatech Pharma PLC Announces MTX110 Development for the Treatment of GliomaMidatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma
finance.yahoo.com - June 21 at 4:04 AM
Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022
yahoo.com - June 10 at 3:47 AM
Midatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBMMidatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBM
uk.investing.com - June 7 at 8:40 PM
Midatech Pharma plc [MTP] Revenue clocked in at $0.70 million, down -28.57% YTD: What’s Next?Midatech Pharma plc [MTP] Revenue clocked in at $0.70 million, down -28.57% YTD: What’s Next?
dbtnews.com - June 2 at 6:44 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma logo

Benitec Biopharma

NASDAQ:BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
China Health Industries logo

China Health Industries

OTCMKTS:CHHE
China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.
Immune Pharmaceuticals logo

Immune Pharmaceuticals

NASDAQ:IMNP
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Biodexa Pharmaceuticals logo

Biodexa Pharmaceuticals

NASDAQ:MTP
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.